vobarilizumab   

GtoPdb Ligand ID: 8363

Synonyms: ALX-0061
Compound class: Antibody
Comment: Vobarilizumab is an investigational bispecific peptide NanobodyTM which binds soluble IL-6R and human albumin (albumin binding being utilised as a half-life extension methodology). Design and production of ALX-0061 is described in patent US8748581 [2]. Vobarilizumab is being developed for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Preclinical information is published in [6].
The exact NanobodyTM structure being used as ALX-0061 was not revealed in the covering patent [2], but has been disclosed in the INN submission. Annotated peptide sequences for this therapeutic are available from its IMGT/mAb-DB record.
Bioactivity Comments
Binding affinity (KD) for human serum albumin is 22nM [6].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Interleukin-6 receptor Hs Antibody Binding 12.7 pKd - 6
pKd 12.7 (Kd 1.9x10-13 M) [6]